Capital World Investors lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 0.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,101,173 shares of the life sciences company’s stock after buying an additional 124,323 shares during the quarter. Capital World Investors owned approximately 0.13% of Illumina worth $2,636,483,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of ILMN. Nordea Investment Management AB lifted its stake in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Illumina during the 4th quarter valued at $73,532,000. Norges Bank purchased a new position in shares of Illumina during the 4th quarter valued at $70,844,000. State Street Corp lifted its stake in shares of Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after buying an additional 382,520 shares in the last quarter. Finally, Duquesne Family Office LLC purchased a new position in shares of Illumina during the 2nd quarter valued at $28,682,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Insider Buying and Selling at Illumina
In other news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,002,371 shares of company stock valued at $155,472,900. Corporate insiders own 2.90% of the company’s stock.
Illumina Stock Performance
Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm posted $0.97 EPS. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.
Analyst Ratings Changes
ILMN has been the topic of a number of analyst reports. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lifted their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Guggenheim lifted their target price on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $138.38.
Read Our Latest Report on Illumina
Illumina Company Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More
- Five stocks we like better than Illumina
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
